EUSA Pharma

EUSA Pharma is a biopharmaceutical company focused on oncology and rare diseases. It offers Sylvant, a product for the treatment of patients with idiopathic multicentric Castleman’s disease (MCD). The company also provides Qarziba for the treatment of high-risk neuroblastoma and Fotivda for the first-line treatment of adult patients with advanced renal cell carcinoma.

Morgan Prestwich were exclusively retained under a Master Service Agreement (MSA) to build their entire UK, EU, International and US operations (over 130 hires). This included all 3 of their rare diseases launch teams globally:
Above country
- Marketing
- Market Access
- Medical Directors
- Government Affairs
- HR
- Finance

In-country appointments:
GM, Marketing, Medical, Market Access, Sales representatives in:
- Germany
- UK
- Italy
- France
- Spain
- USA
- Central Europe